Terry Onichi Matsunaga, PharmD, PhD
PO Box 245067
Building: AHSC (#5067)
Room #: 1343
Links
Selected Publications
Sponsored Research Through MSRP
NIH Undergraduate Diversity Program
NIH High School Student Research Program
Degrees
- University of California, Berkeley, 1975 (A.B., Biochemistry)
- University of California, San Francisco, 1980 (Pharm. D., Pharmacy)
- University of Michigan, Ann Arbor, 1981 (Residency Certificate, Clinical Pharmacy)
- University of California, San Francisco, 1987 (Ph.D., Pharmaceutical Chemistry)
- University of Arizona, 1989 (Post-Doctoral Fellow, Chemistry)
Awards
- Excellence in Biotechnology Award for Outstanding Achievement in Drug Delivery. Genetic Engineering News. 2004
- American Chemical Society Rocky Mountain Regional Industrial Innovation Award. 2006
- Louis J. Kettel Faculty Mentor Award in Basic Sciences. University of Arizona 2011
Research Interests
Dr. Matsunaga’s laboratory develops ultrasound contrast agents for imaging and novel delivery systems for drug and gene therapy. Dr. Matsunaga has worked along side Dr. Evan Unger, the principal architect, at ImaRx Pharmaceutical Corp. to invent and develop the lipid-coated vascular microbubble agent, Definity® , an FDA-approved echocardiographic contrast agent.
In addition, over the past five years, Dr. Matsunaga focused his attention upon the use of ultrasound-mediated bubble cavitation for dispersion of vascular thrombi. His research interests lie in the area of ultrasound contrast agents and novel drug delivery systems for drug and gene delivery. Dr. Matsunaga regularly sits on grant review study sections for various programs in the NIH (i.e. NIDA, RAID, SBIR, and STTR) and the Department of Defense (Breast Cancer and Prostate Cancer programs).